Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults

• Main Authors: Xiaohua Hao (Author), Zheng Zhang (Author), Ji Ma (Author), Lin Cheng (Author), Yun Ji (Author), Yang Liu (Author), Dong Zhao (Author), Wen Zhang (Author), Chunming Li (Author), Li Yan (Author), David Margolis (Author), Qing Zhu (Author), Yao Zhang (Author), Fujie Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies as a cocktail therapy for treating COVID-19 with a modified Fc region that extends half-life.Methods: Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated in...